Comparing Toxicity Profiles of Immunotherapy Versus BRAF-Targeted Therapy in Melanoma
Ryan J. Sullivan, MD, compares the toxicity profiles of BRAF-targeted therapy and immunotherapy used for the treatment of patients with melanoma.
Analyzing the Role of Checkpoint Inhibitors for the Treatment of Melanoma
Ryan J. Sullivan, MD, discusses the role of checkpoint inhibitors in the treatment landscape for patients with melanoma.
New and Emerging Therapies for Metastatic Melanoma
Ryan J. Sullivan, MD, medical oncologist, Massachusetts General Hospital, gives an overview of new and emerging therapies for the treatment of metastatic melanoma.